Form 4: PAVmed Director Timothy Baxter Granted 150,000 Restricted Shares

PAVmed Inc. Director Timothy E. Baxter received a grant of 150,000 restricted common shares, increasing his beneficial ownership to 215,000 shares.

Summary

• Timothy E. Baxter, a Director of PAVmed Inc., was granted 150,000 shares of common stock.
• This grant was made under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan.
• The restricted stock has a single vesting date of May 20, 2028, and is subject to forfeiture if the requisite service period is not completed.
• Following this transaction, Mr. Baxter beneficially owns 215,000 shares of PAVmed Inc. common stock.
• The transaction date for the grant was September 30, 2025.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a director is a routine corporate governance event, generally viewed as positive for aligning management/director interests with shareholders, but it doesn't represent new operational or financial performance news.

Positives

• Indicates continued commitment of a director to the company through long-term incentive equity.
• Aligns director's interests with long-term shareholder value through restricted stock vesting over time.

Negatives

• No immediate cash investment by the director, as the grant price was $0.

Risks

• The restricted stock is subject to forfeiture if the requisite service period is not completed, meaning the director must remain with the company until May 20, 2028, to fully realize the shares.

Future Outlook

The vesting schedule implies a future commitment from the director until May 20, 2028, aligning their long-term interests with the company's performance.

Industry Context

Equity grants to directors are a common practice in publicly traded companies, particularly in the healthcare and medical device sectors (where PAVmed operates), to incentivize long-term commitment and align interests with shareholders. This is a standard compensation mechanism.

Comparison to Industry Standards

• Equity-based compensation, particularly restricted stock units (RSUs) or restricted stock, is a standard component of director compensation packages across various industries, including biotech and medical devices. Companies like Medtronic, Johnson & Johnson, or smaller biotech firms frequently use similar long-term incentive plans to retain and motivate key personnel and board members.
• The $0 grant price is typical for restricted stock awards, which derive their value from the underlying stock price appreciation.
• The vesting period of approximately 2.5 years (from filing date to May 2028) is also within common industry ranges for such grants, aiming to ensure sustained commitment.

Related Party Transactions

• The grant of restricted stock to Timothy E. Baxter, a Director, constitutes a related party transaction, which is a standard form of compensation under the company's existing equity plan.

Stakeholder Impact

• Shareholders: Aligns the director's long-term interests with shareholder value. Any potential dilution from new shares is typically minimal in the context of total outstanding shares.
• Management/Directors: Timothy E. Baxter receives additional equity compensation, incentivizing continued service and commitment to the company's long-term success.

Next Steps

• The restricted stock will vest on May 20, 2028, assuming the requisite service period is completed.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director as part of their compensation package. While it indicates continued alignment of interests between the director and shareholders, it does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It's a standard governance disclosure.

Keywords

PAVmed, PAVM, Timothy Baxter, Restricted Stock, Equity Grant, Director Compensation, Insider Ownership, Form 4